---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-036123"
form_type: "8-K"
ticker: "XAGE"
cik: "0001842939"
company_name: "Longevity Health Holdings, Inc."
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T08:01:20.153319+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Carmell sells Axolotl Biologix subsidiary for shares and $8M note cancellation

## Summary
- Returns 3,845,337 common shares and 4,243 preferred shares to original sellers; cancels $8 million note payable.
- Exits tissue graft space; sharpens focus on skincare product launches beginning March 2024 through Summer 2024.
- Expects $4 million annualized drop in cash burn net of revenue from AxoBio's January 2024 run rate.
- Reduces total debt by $15.6 million ($7.6M sub debt + $8M note); adds $7M tangible equity; cuts EPS dilution 29%.
- Post-closing: 19.25 million common shares outstanding; retained focus on aesthetics pipeline.

## SEC filing metadata
- accession: 0000950170-24-036123
- form_type: 8-K
- ticker: XAGE
- cik: 0001842939
- company_name: Longevity Health Holdings, Inc.
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842939/000095017024036123/0000950170-24-036123-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842939/000095017024036123/ctcx-20240320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-036123
- JSON: https://secwatch.observer/filing/0000950170-24-036123.json
- Plain text: https://secwatch.observer/filing/0000950170-24-036123.txt

## Key facts
- Material Agreements
  Longevity Health Holdings, Inc. entered into Membership Interest Purchase Agreement with Burns Ventures, LLC, H. Rodney Burns, AXO XP, LLC, and Protein Genomics, LLC (effective 2024-03-20).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Burns Ventures, LLC, H. Rodney Burns, AXO XP, LLC, and Protein Genomics, LLC
  - Effective: 2024-03-20
  source text: On March 20, 2024, Carmell Corporation, a Delaware corporation (the “Company”), and Axolotl Biologix, LLC, a Delaware limited liability company and a wholly owned subsidiary of the Company (“AxoBio”), entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”), with the stockholders of AxoBio immediately before the Merger (as defined below), including Burns Ventures, LLC, a Texas limited liability company (“BVLLC”), H. Rodney Burns, an individual resident of Texas (“Burns”), AXO XP, LLC, an Arizona limited liability company (“AXPLLC”), and Protein Genomics, LLC, a Delaware corporation (“PGEN” and together with BVLLC, Burns, and AXPLLC, collectively, the “Buyers” and each, a “Buyer”), providing for, upon the terms and subject to the conditions set forth therein, the sale by the Company of all outstanding limited liability company interests of AxoBio to the Buyers (the “Sale”) for the consideration described in detail below.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1842939/000095017024036123/0000950170-24-036123-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.